Could Receptors for Advanced Glycation End Products Be Considered Cardiovascular Risk Markers in Obese Children?

2012 ◽  
Vol 17 (2) ◽  
pp. 187-191 ◽  
Author(s):  
Tommaso de Giorgis ◽  
Ebe D'Adamo ◽  
Cosimo Giannini ◽  
Valentina Chiavaroli ◽  
Antonino Scarinci ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Advanced Glycation End Products ◽  
Risk Markers ◽  
Obese Children ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Receptor of advanced glycation end products and cardiovascular risk in elderly with type 2 diabetes mellitus

2018 ◽  
Vol 90 (2) ◽  
Author(s):  
Claudia Borsa ◽  
Daniela Gradinaru ◽  
Denisa Margina ◽  
Gabriel Ioan Prada ◽  
Catalina Pena
Keyword(s):  
Cardiovascular Risk ◽  
Advanced Glycation End Products ◽  
Vascular Complications ◽  
Elderly Subjects ◽  
Risk Markers ◽  
Advanced Glycation ◽  
Soluble Rage ◽  
Glycation End Products ◽  
End Products

The interaction of Advanced Glycation End products (AGEs) and their specific receptor, Receptor for Advanced Glycation End products (RAGE) play an important role in diabetes and vascular complications. Engagement of RAGE by AGEs leads to activation of cellular signaling pathways and vascular dysfunction. The soluble RAGE (sRAGE) acts as a decoy receptor for AGEs. The aim of this study was to evaluate the soluble RAGE in elderly subjects with T2DM and its relationships with glycoxidative, inflammatory and cardiovascular risk markers. The serum AGEs, sRAGE, interleukine- 6 (IL-6), lipid profile, glycemic status, uric acid, creatinine and cardiovascular risk markers were determined in elderly subjects with type 2 diabetes mellitus (T2DM, N=72, 75±4 years old) and aged-match healthy subjects (N=15, 76±3 years old). Significant higher levels of AGEs and AGEs/sRAGE ratio concomitantly with significant lower levels of sRAGE were pointed out in elderly subjects with T2DM as compared to control. The values of AGEs/sRAGE ratio were significantly positively associated (P<0.05) with atherogenic, inflammatory and cardiovascular risk markers and significantly negatively with anti-atherogenic lipoproteins (P<0.05). The multivariate regression analyses showed that atherogenic index was an independent predictor of sRAGE levels and AGEs/sRAGE ratio values. The associations of soluble RAGE and the AGEs/sRAGE ratio with atherogenic and inflammatory markers could reflect the protective role of soluble variants of RAGE in atherosclerosis and diabetes vascular complications.

scholarly journals Advanced glycation end products (AGEs) estimated by skin autofluorescence are related with cardiovascular risk in renal transplant

PLoS ONE ◽  
2018 ◽  
Vol 13 (8) ◽  
pp. e0201118 ◽  
Author(s):  
Jesus Calviño ◽  
Secundino Cigarran ◽  
Lourdes Gonzalez-Tabares ◽  
Nicolas Menendez ◽  
Juan Latorre ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Renal Transplant ◽  
Advanced Glycation End Products ◽  
Skin Autofluorescence ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Advanced Glycation End Products in Recent-Onset Psychosis Indicate Early Onset of Cardiovascular Risk

2017 ◽  
Vol 78 (9) ◽  
pp. 1395-1401 ◽  
Author(s):  
Julia M. Hagen ◽  
Arjen L. Sutterland ◽  
Maarten W. Koeter ◽  
Rene Lutter ◽  
Dan Cohen ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Advanced Glycation End Products ◽  
Early Onset ◽  
Advanced Glycation ◽  
Recent Onset ◽  
Glycation End Products ◽  
End Products

scholarly journals Plasma Catestatin Levels and Advanced Glycation End Products in Patients on Hemodialysis

Biomolecules ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 456
Author(s):  
Mirko Luketin ◽  
Maja Mizdrak ◽  
Dijana Boric-Skaro ◽  
Dinko Martinovic ◽  
Daria Tokic ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Advanced Glycation End Products ◽  
Significant Positive Correlation ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls ◽  
Advanced Glycation ◽  
Positive Correlation ◽  
Glycation End Products ◽  
End Products ◽  
Stage Renal Disease

Catestatin (CST) is a pleiotropic peptide involved in cardiovascular protection with its antihypertensive and angiogenic effects. Considering that patients with end-stage renal disease (ESRD) who are undergoing hemodialysis (HD) are associated with higher cardiovascular risk, the aim of this study was to investigate plasma CST levels in HD patients, compare them to healthy controls and evaluate possible CST associations with advanced glycation end products (AGEs) and laboratory, anthropometric and clinical parameters. The study included 91 patients on HD and 70 healthy controls. Plasma CST levels were determined by an enzyme-linked immunosorbent assay in a commercially available diagnostic kit, while AGEs were determined using skin autofluorescence. Plasma CST levels were significantly higher in the HD group compared to the controls (32.85 ± 20.18 vs. 5.39 ± 1.24 ng/mL, p < 0.001) and there was a significant positive correlation between CST and AGEs (r = 0.492, p < 0.001). Furthermore, there was a significant positive correlation between plasma CST levels with both the Dialysis Malnutrition Score (r = 0.295, p = 0.004) and Malnutrition-Inflammation Score (r = 0.290, p = 0.005). These results suggest that CST could be playing a role in the complex pathophysiology of ESRD/HD and that it could affect the higher cardiovascular risk of patients on HD.

Plasma advanced glycation end products are decreased in obese children compared with lean controls

2009 ◽  
Vol 4 (2) ◽  
pp. 112-118 ◽  
Author(s):  
Katarína Šebeková ◽  
Veronika Somoza ◽  
Monika Jarčušková ◽  
August Heidland ◽  
Ludmila Podracká
Keyword(s):  
Advanced Glycation End Products ◽  
Obese Children ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products
Sign in / Sign up

Export Citation Format

Share Document